How is the Adult Malignant Glioma Therapeutics Market Poised for Growth: Trends and Opportunities Through 2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the adult malignant glioma therapeutics market grown in recent years?
The market for therapies treating adult malignant glioma has experienced rapid expansion in recent periods. The market, valued at $2.25 billion in 2024, is projected to reach $2.48 billion in 2025, thanks to a compound annual growth rate (CAGR) of 10.4%. The historical growth in the sector could be linked to factors such as the rise in occurrence rates, efforts from patient advocacy groups, and the adoption of personalized medicine strategies.
How is the adult malignant glioma therapeutics market size expected to evolve during the forecast period?
Expectations are high for the adult malignant glioma therapeutics market to experience substantial growth in the coming years. The projected value of the market is set to grow to $3.55 billion by 2029, showcasing a compound annual growth rate (CAGR) of 9.4%. This forecasted growth can be linked to advancements in immunotherapy, targeted therapies, biomarker discoveries, applications of liquid biopsy, and expanded access programs. Key trends that are expected to influence the market during this forecast period include the advancement of patient-centric drug development, quickened and breakthrough designations, modernization in drug delivery systems, collective research initiatives, and the integration of artificial intelligence.
Get your adult malignant glioma therapeutics market report here!
Which key drivers are propelling the adult malignant glioma therapeutics market’s growth?
The escalating instances of brain tumors are projected to stimulate the growth of the adult malignant glioma therapeutics market. Brain tumors typically involve an abnormal proliferation of tissue, where cell growth appears to be unregulated and rampant. Adult malignant glioma is a specific type of brain tumor, consisting of cells that grow in an erratic and unchecked manner. Its treatment involves a combination of surgical procedures, radiation therapy, and chemotherapy. As per data from the American Cancer Society published in January 2023, there has been a rise in brain and nervous system cancer cases – 24,810 in 2023, marking a 3.85% increase from 23,890 in 2020. Therefore, a surge in brain tumors gives impetus to the adult malignant glioma therapeutics market.
Adult Malignant Glioma Therapeutics Market Driver: Government Funding Fuelling Advancements In Adult Malignant Glioma Therapeutics
What are the market segments in the adult malignant glioma therapeutics industry?
The adult malignant glioma therapeutics market covered in this report is segmented –
1) By Type Of Disease: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Other Types
2) By Therapy: Chemotherapy, Targeted Therapy, Radiotherapy, Other Therapies
3) By End-User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers, Other End Users
Subsegments:
1) By Glioblastoma Multiforme: Standard Treatments, Experimental Therapies
2) By Anaplastic Astrocytoma: Chemotherapy Options, Targeted Therapies
3) By Anaplastic Oligodendroglioma: Radiation Therapy, Combination Therapies
4) By Anaplastic Oligoastrocytoma: Surgical Interventions, Adjuvant Therapies
5) By Other Types: Rare Gliomas, Emerging Therapies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13178&type=smp
Which leading companies are shaping the growth of the adult malignant glioma therapeutics market?
Major companies operating in the adult malignant glioma therapeutics market report are Johnson & Johnson Private Limited, Pfizer Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Allergan PLC, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Abbott Laboratories, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genetech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.
What key trends are currently impacting the adult malignant glioma therapeutics market’s development?
Leading businesses in the adult malignant glioma therapeutics market are introducing innovative solutions like small molecule targeted degraders to enhance their customer service. These drugs leverage small molecules to initiate the breakdown of specific proteins by focusing on the proteins of interest (POI) and an E3 ubiquitin ligase. For example, in February 2023, Beactica Therapeutics AB, a precision oncology company based in Sweden, secured orphan drug designation approval from the U.S. Food and Drug Administration (FDA) for BEA-17, meant for treating glioblastoma (GBM). This small molecule targeted degrader is designed to disintegrate the epigenetic enzyme LSD1 and its co-factor CoREST, implicated in the emergence of various cancers including GBM. BEA-17 functions by degrading LSD1 and CoREST, resulting in the reactivation of tumor suppressor genes and inhibits the growth of cancer cells.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13178
Which geographic areas are influencing the growth of the adult malignant glioma therapeutics market?
North America was the largest region in the adult malignant glioma therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult malignant glioma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Pet Cancer Therapeutics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/pet-cancer-therapeutics-global-market-report
Leukemia Therapeutics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report
Liver Diseases Therapeutics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
